Cotinga Pharmaceuticals Inc.
http://cotingapharma.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Cotinga Pharmaceuticals Inc.
Amgen's KRAS Inhibitor AMG 510 Leans Toward Tumor-Dependent, Not Agnostic, Approach
SVP Elliott Levy said the company hasn't ruled out a tumor-agnostic approach for AMG 510, but Phase I data for the first-in-class drug show a bigger effect in lung cancer – a 50% response rate, so far – than in colorectal cancer patients with a KRAS G12C mutation.
Execs On The Move, January 2017
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
Recent Tech Transfer Deals, October 2012
START-UP’s monthly update on technology transfer deals—licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, medical devices, pharmaceuticals, and research/analytical equipment & supplies.
Company Information
- Industry
- Pharmaceuticals
-
Biotechnology
-
Drug Discovery Tools
- ADMET
- Bioinformatics
- Molecular Diversity
-
Drug Discovery Tools
- Other Names / Subsidiaries
-
- Critical Outcome Technologies Inc.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice